Massimo Cristofanilli, MD
Despite advances made in disease biology and detection, treatment for patients with ESR1
-mutated, estrogen receptor (ER)–positive, HER2-negative breast cancer continues to be an area of unmet need, according to Massimo Cristofanilli, MD. As more patients develop resistance to available agents, he adds, the need for novel safer and more effective therapies is emphasized.
... to read the full story